Glycaemic control after early mobilisation in patients on haemodialysis: A randomised controlled trial
Published
January 11, 2025
Paper ID
PAP-000069
Status
Published
DOI
10.65712/tmj.test000327
Advance Services
Abstract
Background: Practice around early mobilisation varies widely between centres. Methods: Analyses were adjusted for age, sex and baseline severity. Results: Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. Conclusion: Implementation will depend on staffing, cost and local protocols.
Introduction
Earlier studies of early mobilisation were small or single-centre. The cost of glycaemic control to health systems is substantial. glycaemic control remains a leading cause of avoidable harm among patients on haemodialysis.
Practice around early mobilisation varies widely between centres. Guidelines make only a weak recommendation on early mobilisation. Earlier studies of early mobilisation were small or single-centre.
The cost of glycaemic control to health systems is substantial. Earlier studies of early mobilisation were small or single-centre.
Discussion
These findings suggest that early mobilisation is associated with better glycaemic control in patients on haemodialysis. Residual confounding cannot be excluded.
Implementation will depend on staffing, cost and local protocols. Future work should test early mobilisation in a pragmatic multicentre trial. These findings suggest that early mobilisation is associated with better glycaemic control in patients on haemodialysis.
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded.
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
These findings suggest that early mobilisation is associated with better glycaemic control in patients on haemodialysis. Strengths include the sample size and blinded outcome assessment. Future work should test early mobilisation in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Conclusions
Early mobilisation is a reasonable option for patients on haemodialysis to improve glycaemic control.
References
1. Ahmed B, Herrera V, et al. High-flow nasal oxygen and 30-day readmission. JAMA. 2018;137(12):508-1153.
2. Osei O, Farouk L, et al. An antibiotic stewardship programme and time to diagnosis. Crit Care Med. 2023;327(8):642-1054.
3. Mensah U, Farouk S, et al. Early enteral nutrition and acute kidney injury. Pediatrics. 2018;167(1):484-1587.
4. Ahmed M, Yilmaz I, et al. Tranexamic acid and emergency department revisits. Lancet. 2024;162(2):851-1008.
5. Dubois F, Kowalski R, et al. Nurse-led discharge planning and glycaemic control. Pediatrics. 2023;278(7):790-1340.
6. Moreau S, Mensah L, et al. Vitamin D supplementation and medication adherence. Ann Intern Med. 2024;115(4):47-1789.
7. Ahmed S, Mensah E, et al. Nurse-led discharge planning and health-related quality of life. Lancet. 2019;70(1):433-1683.
8. Andersen L, Yilmaz E, et al. Point-of-care ultrasound and falls. Pediatrics. 2023;233(7):619-1496.
9. Okafor T, Zhang J, et al. Continuous glucose monitoring and ventilator-free days. JAMA. 2020;99(11):661-1763.
Appendices
Supplementary tables are available on request.
Materials and Methods
Missing data were handled with multiple imputation. The primary outcome was glycaemic control, assessed blind to allocation.
The primary outcome was glycaemic control, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity. We conducted a randomised controlled trial across 4 centres between 2016 and 2022.
The primary outcome was glycaemic control, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.
Results
2074 participants were included (median age 58 years). glycaemic control occurred in 13% of the intervention group versus 27% of controls. glycaemic control occurred in 14% of the intervention group versus 12% of controls. 2847 participants were included (median age 71 years).
| Group | n | Events | Rate % |
|---|---|---|---|
| Male | 399 | 65 | 8.4 |
| Female | 892 | 80 | 13.8 |
| Centre A | 696 | 13 | 12.6 |
| Centre A | 697 | 119 | 8.2 |
Values are n (%) unless stated otherwise.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. 1405 participants were included (median age 69 years).